Sana Biotechnology Inc (SANA)

Sana Biotechnology, Inc. is a Seattle-based biotechnology company focused on engineered cell therapies designed to function as medicines. Its work centers on ex vivo and in vivo cell engineering platforms aimed at areas with significant unmet medical need, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s pipeline includes UP421, a HIP-modified allogeneic primary islet cell product in phase 1 testing for type 1 diabetes, and SC451, a stem cell-derived pancreatic islet cell therapy that is in preclinical development for the same condition. Sana is also developing SG293 and SG299, which are CD8-targeted fusosome programs intended for B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has collaborations and licensing arrangements with Beam Therapeutics and Harvard College, and a strategic partnership with Mayo Clinic related to SC451. Founded in 2018, the company previously operated as FD Therapeutics, Inc. before adopting its current name in 2018.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.